Compare Regeneron Pharmaceuticals Inc (REGN) vs Zscaler Inc (ZS) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.

Zscaler (ZS) trades at $213.55, up 0.61% with strong technical momentum as the stock approaches resistance near $216. The company demonstrates robust revenue growth, increasing from $1.1B in 2022 to $2.67B in 2025, while narrowing net losses from -$390M to -$41M. Recent earnings beats and 79.6% analyst buy ratings support positive sentiment, though negative profitability metrics and high valuation multiples present challenges.

The outlook remains cautiously optimistic with a $222.83 consensus price target suggesting 4.3% upside potential. Key opportunities include accelerating AI security demand and expanding platform adoption, while risks involve continued profitability challenges, executive transitions, and competitive pressures in the cybersecurity sector.